Hepatic Drug Dosing in ICU

Answer Card

Answer: Hepatic drug dosing in critical illness requires understanding of liver physiology, drug metabolism pathways, and the impact of liver disease on pharmacokinetics. The liver receives 25-30% of cardiac output via dual blood supply (portal vein 70-80%, hepatic artery 20-30%) and is the primary site for drug metabolism through phase I reactions (CYP450 oxidation, reduction, hydrolysis) and phase II reactions (glucuronidation, sulfation, acetylation, glutathione conjugation).

Key concepts: Hepatic extraction ratio determines whether drug clearance is flow-dependent (high extraction, ER greater than 0.7) or capacity-dependent (low extraction, ER below 0.3). Child-Pugh classification (scores 5-15) and MELD score predict liver disease severity and guide dosing adjustments. First-pass metabolism significantly affects oral bioavailability, which may increase dramatically with portosystemic shunting in cirrhosis. Critically ill patients often have altered hepatic blood flow due to shock, vasopressors, and mechanical ventilation, necessitating individualized drug dosing and therapeutic drug monitoring.

Common ICU drug adjustments: High-extraction drugs (morphine, propofol, lidocaine, fentanyl) require 25-50% dose reduction in moderate-severe liver disease. Midazolam clearance reduced 50% in Child-Pugh B. Rocuronium prolonged 2-3-fold in severe liver failure. Antibiotics like ceftriaxone require caution, while meropenem generally safe.

Summary Table: Hepatic Drug Classification

Clinical Overview

The liver is the primary metabolic organ for the majority of drugs used in intensive care. Understanding hepatic drug metabolism is essential because liver disease significantly alters pharmacokinetics, leading to either therapeutic failure or drug toxicity. Approximately 30-40% of ICU patients have some degree of hepatic dysfunction, and liver failure mortality in ICU remains high at 50-80% (PMID 22546102).

Drug metabolism in the liver occurs through two major phases:

• Phase I reactions: CYP450-mediated oxidation, reduction, hydrolysis, creating more polar metabolites
• Phase II reactions: Conjugation reactions (glucuronidation, sulfation, acetylation, glutathione) that generally increase water solubility for elimination

In critically ill patients, multiple factors affect hepatic drug handling:

1. Altered hepatic blood flow due to shock, vasopressors, mechanical ventilation (positive pressure reduces portal flow)
2. Hypoalbuminemia increases free drug concentration for highly protein-bound drugs
3. Portosystemic shunting bypasses first-pass metabolism, increasing oral bioavailability
4. CYP450 enzyme induction or inhibition from concurrent medications
5. Accumulation of endogenous toxins that compete for metabolic pathways

Epidemiology

Liver disease in critically ill patients is common and associated with poor outcomes:

• Cirrhosis prevalence: 1-2% in general population, 5-10% in ICU admissions (PMID 27454991)
• Acute-on-chronic liver failure (ACLF): Occurs in 30-40% of hospitalized cirrhotics, with ICU mortality 50-80% (PMID 20038932)
• Drug-induced liver injury: Accounts for 10-15% of acute liver failure cases (PMID 21409395)
• Hypoalbuminemia: Present in 40-50% of ICU patients, affecting highly protein-bound drugs (PMID 23897031)

High-risk populations:

• Alcoholic liver disease: 40-60% of cirrhosis cases in Australia/NZ (PMID 25884267)
• Non-alcoholic fatty liver disease (NAFLD): Increasing prevalence, 20-30% in obese ICU patients (PMID 26512146)
• Viral hepatitis (HBV, HCV): Significant burden in Asia-Pacific region
• Indigenous Australians: 2-3x higher rates of alcohol-related liver disease (PMID 28336795)

Pathophysiology

Hepatic Blood Flow and Drug Clearance

The liver receives approximately 25-30% of resting cardiac output (1,200-1,500 mL/min) through dual blood supply:

Portal Vein (70-80%):

• Blood flow: 800-1,200 mL/min
• Source: Splanchnic circulation (stomach, intestines, spleen, pancreas)
• Rich in absorbed nutrients and orally administered drugs
• Flow decreases with: hypovolemia, increased intra-abdominal pressure (PPV, ascites), splanchnic vasoconstriction (vasopressors, catecholamines)

Hepatic Artery (20-30%):

• Blood flow: 300-500 mL/min
• Source: Celiac trunk
• Provides oxygen-rich blood
• Autoregulatory compensation: Hepatic arterial buffer response maintains total hepatic blood flow when portal flow changes (PMID 24863621)

Hepatic Extraction Ratio (ER):

ER = (Cin - Cout) / Cin

Where:

• ER greater than 0.7 = High extraction (flow-limited)
• ER 0.3-0.7 = Intermediate extraction
• ER below 0.3 = Low extraction (capacity-limited)

Clinical significance: For high extraction drugs, clearance (Cl) ≈ hepatic blood flow (Q):

• Cl ≈ Q × ER
• If hepatic blood flow decreases 50%, clearance decreases approximately 50%
• Low extraction drugs are minimally affected by blood flow changes but more affected by enzyme inhibition or liver disease (PMID 24939521)

Phase I Metabolism (CYP450 System)

Cytochrome P450 enzymes are heme-containing monooxygenases primarily located in hepatocyte smooth endoplasmic reticulum. Major isoforms:

CYP3A4/5:

• Metabolizes: 40-50% of all drugs
• Substrates: Midazolam, fentanyl, propofol, calcium channel blockers, statins, macrolides
• Inducers: Rifampin, carbamazepine, phenytoin, glucocorticoids
• Inhibitors: Macrolides, azole antifungals, protease inhibitors, grapefruit juice
• Decreases 50-70% in severe liver disease (PMID 24362526)

CYP2D6:

• Metabolizes: Codeine, tramadol, ondansetron, beta-blockers (metoprolol), antipsychotics
• Genetic polymorphism: Poor metabolizers (5-10%), ultra-rapid metabolizers (1-2%)
• Generally preserved until late-stage liver disease (PMID 24237006)

CYP2C9:

• Metabolizes: Phenytoin, NSAIDs, warfarin, losartan
• Decreases 40-50% in cirrhosis (PMID 25413442)

CYP1A2:

• Metabolizes: Theophylline, caffeine, clozapine, olanzapine
• Highly sensitive to inflammation and cytokines (PMID 2617631)

Factors affecting CYP450 activity in critical illness:

1. Inflammatory mediators: TNF-α, IL-1, IL-6 downregulate CYP450 enzymes ("acute phase response")
2. Cholestasis: Bile acids can induce or inhibit various CYPs
3. Hypoxia: Decreases CYP450 activity through reduced oxygen availability
4. Nutritional status: Malnutrition reduces enzyme synthesis
5. Concurrent medications: Drug-drug interactions via inhibition/induction

Phase II Metabolism (Conjugation Reactions)

Phase II reactions generally preserve activity longer than phase I in liver disease but are not completely spared:

Glucuronidation (UGT enzymes):

• Enzymes: UDP-glucuronosyltransferases
• Substrates: Morphine, lorazepam, paracetamol, midazolam, zolpidem
• Generally preserved until severe liver disease
• Morphine-6-glucuronide (active metabolite) accumulation in renal failure (PMID 15302684)

Sulfation (SULT enzymes):

• Enzymes: Sulfotransferases
• Substrates: Paracetamol, minoxidil, steroids
• Decreased capacity in cirrhosis, may shift metabolism to oxidative pathways (PMID 29029961)

Acetylation (NAT enzymes):

• Enzymes: N-acetyltransferases
• Substrates: Isoniazid, procainamide, hydralazine
• Genetic polymorphism: Slow vs fast acetylators
• Generally preserved (PMID 28263102)

Glutathione conjugation (GST enzymes):

• Enzymes: Glutathione S-transferases
• Critical for: Paracetamol detoxification, reactive metabolites
• Depleted in chronic liver disease, paracetamol toxicity (PMID 12069671)

First-Pass Metabolism

First-pass metabolism refers to the extraction of orally administered drugs during their initial passage through the liver after intestinal absorption.

Bioavailability (F) for oral drugs: F = f × (1 - ER)

Where:

• f = Fraction absorbed from GI tract
• ER = Hepatic extraction ratio

Clinical examples:

• Morphine: ER ~0.7, Oral bioavailability ~30% (IV dose 10 mg ≈ PO dose 30 mg)
• Propranolol: ER ~0.8, Oral bioavailability ~25%
• Lidocaine: ER ~0.7, First-pass so extensive that PO administration ineffective for antiarrhythmic effect
• Midazolam: ER ~0.4-0.6, Oral bioavailability 40-60%

Impact of liver disease:

• Reduced hepatic metabolic capacity → decreased extraction → increased bioavailability
• Portosystemic shunts → bypass first-pass metabolism → dramatically increased bioavailability (up to 100%)
• Clinical consequence: Standard oral doses may become toxic in cirrhosis (PMID 19318353)

Positive pressure ventilation:

• Decreases venous return by 10-30%
• Reduces portal venous flow
• May increase oral bioavailability of high extraction drugs by 20-40% (PMID 14732749)

Protein Binding and Hypoalbuminemia

Drug binding to plasma proteins affects:

• Volume of distribution (Vd)
• Free (active) drug concentration
• Hepatic clearance (only unbound drug is available for metabolism)

Key binding proteins:

• Albumin: Binds acidic drugs (warfarin, phenytoin, NSAIDs, propofol)
• α1-acid glycoprotein: Binds basic drugs (propranolol, lidocaine, antidepressants)

Hypoalbuminemia in ICU:

• Common in: sepsis, trauma, burns, malnutrition, liver disease
• Albumin below 20 g/L: 30-40% of ICU patients (PMID 17082784)
• Effect: Increased free fraction of highly bound drugs, may require dose reduction

Examples:

• Phenytoin: 90% albumin-bound, free fraction increases from 10% → 20% when albumin 20 g/L → potential toxicity despite "therapeutic" total levels
• Propofol: 98-99% protein-bound, sedation prolonged with hypoalbuminemia
• Warfarin: Highly albumin-bound, increased anticoagulant effect with hypoalbuminemia (PMID 29043421)

Important concept: Routine drug level monitoring typically measures total drug. In hypoalbuminemia, interpret with caution or measure free levels.

Classification Systems

Child-Pugh Classification

The Child-Pugh score (also called Child-Turcotte-Pugh) assesses severity of chronic liver disease and correlates with prognosis.

Scoring System:

Classification:

• Child-Pugh A: Score 5-6 points (well-compensated)
• Child-Pugh B: Score 7-9 points (moderate impairment)
• Child-Pugh C: Score 10-15 points (severe impairment)

Prognosis:

• 1-year survival: Child A 100%, Child B 80%, Child C 45% (PMID 2350114)
• 2-year survival: Child A 85%, Child B 60%, Child C 35%
• Surgical mortality: Elective surgery contraindicated in Child-Pugh C (PMID 9855325)

Drug dosing implications:

Specific examples:

• Morphine: Child A: standard dosing; Child B: reduce 50%; Child C: avoid or use fentanyl at 25% dose (PMID 9428820)
• Midazolam: Child A: standard; Child B: reduce 50%; Child C: avoid, use lorazepam (PMID 17071272)
• Rocuronium: Child A: standard; Child B: prolonged effect, monitor train-of-four; Child C: 50% dose, prolonged neuromuscular blockade (PMID 29083736)
• Ceftriaxone: Child A: standard; Child B: standard; Child C: avoid (biliary precipitation risk) (PMID 23201312)

MELD Score

The Model for End-Stage Liver Disease (MELD) score is a more objective prognostic score derived from three laboratory parameters.

MELD Equation:

MELD = 3.78 × ln[bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[creatinine (mg/dL)] + 6.43

MELD-Na (includes sodium): MELD-Na = MELD - Na - [0.025 × MELD × (140 - Na)] + 140

Where sodium is in mmol/L (capped at 125-140 mmol/L)

Interpretation:

• MELD below 10: Minimal mortality risk (3-month survival ~95%)
• MELD 10-19: Moderate risk (3-month survival ~75%)
• MELD 20-29: Severe (3-month survival ~50%)
• MELD 30-39: Very severe (3-month survival ~30%)
• MELD ≥40: Critical (3-month survival ~20%)

Advantages over Child-Pugh:

• Objective (no subjective components)
• Uses continuous variables (less "clustering")
• Better predictor of mortality in chronic liver disease
• Used for organ allocation (PMID 11020664)

Drug dosing by MELD score:

MELD vs Child-Pugh for drug dosing:

• Child-Pugh better reflects functional status and encephalopathy risk
• MELD better for objective assessment of synthetic function
• Use both in clinical practice (PMID 8806968)

Hepatic Encephalopathy Grading

West Haven Criteria for hepatic encephalopathy (HE):

Drug implications:

• Grade 0-1: Standard drug dosing with hepatic impairment considerations
• Grade 2-3: Additional 25% dose reduction due to impaired clearance and increased CNS sensitivity
• Grade 4: Minimal drug use, avoid sedatives that may worsen encephalopathy (PMID 17082784)

Sedatives to avoid in HE:

• Benzodiazepines (especially long-acting: diazepam, clonazepam)
• Barbiturates
• Chlorpromazine and other phenothiazines
• Opioids (reduce dose 50% or use alternative analgesics)

Sedatives preferred in HE:

• Lorazepam: Glucuronidated (minimal phase I metabolism), no active metabolites, short half-life
• Oxazepam: Similar to lorazepam
• Remifentanil: Esterase metabolism (non-hepatic), titratable, ultra-short acting
• Dexmedetomidine: Minimal hepatic metabolism, preserves arousability (PMID 29043421)

High Extraction Ratio Drugs

High extraction ratio (ER greater than 0.7) drugs are flow-dependent, meaning their clearance is primarily determined by hepatic blood flow rather than enzyme activity.

Pharmacokinetic principle:

Cl = Q × ER

Where:

• Cl = Hepatic clearance
• Q = Hepatic blood flow
• ER = Extraction ratio

For high ER drugs, clearance directly proportional to hepatic blood flow:

• 50% reduction in hepatic flow → ~50% reduction in clearance
• Requires 50% reduction in maintenance dose to maintain steady-state concentration

Clinical significance in ICU:

1. Shock states (cardiogenic, septic, hypovolemic): Decreased cardiac output → decreased hepatic blood flow → decreased clearance → drug accumulation
2. Vasopressors (norepinephrine, epinephrine): Maintain MAP but cause splanchnic vasoconstriction → reduced portal flow → decreased clearance
3. Positive pressure ventilation: Reduces venous return → reduced portal flow
4. Ascites and increased intra-abdominal pressure: Compresses portal vein → reduced flow

Common high extraction drugs in ICU:

Opioids

Morphine:

• ER: 0.6-0.7
• First-pass metabolism: 60-70% oral bioavailability (increases to near 100% in cirrhosis due to shunting)
• Metabolism: Hepatic glucuronidation to morphine-6-glucuronide (M6G, active, 10-50x more potent than morphine) and morphine-3-glucuronide (M3G, neuroexcitatory)
• Renal elimination of glucuronide metabolites
• Dosing in liver disease:
  • "Child-Pugh A: Standard dosing"
  • "Child-Pugh B: Reduce by 50%"
  • "Child-Pugh C: Avoid (use fentanyl at 25% dose or remifentanil)"
• Monitoring: Respiratory depression, prolonged sedation, M6G accumulation in renal dysfunction (PMID 9428820)

Fentanyl:

• ER: 0.7-0.8
• First-pass metabolism: Extensive, oral bioavailability below 10%
• Metabolism: Hepatic CYP3A4 to norfentanyl (inactive)
• Highly lipophilic → large Vd → prolonged context-sensitive half-time with prolonged infusions
• Dosing in liver disease:
  • "Child-Pugh A: Standard dosing"
  • "Child-Pugh B: Reduce by 25-50%"
  • "Child-Pugh C: Reduce by 50-75%"
• Advantage: Less histamine release than morphine (more hemodynamically stable)
• Monitoring: Chest wall rigidity (wooden chest syndrome) with rapid bolus (especially in liver disease) (PMID 15302684)

Alfentanil:

• ER: ~0.4-0.6 (intermediate)
• Metabolism: CYP3A4
• Context-sensitive half-time less dependent on infusion duration than fentanyl
• Dosing in liver disease: Similar to fentanyl, reduce 25-50% in moderate-severe disease

Remifentanil:

• ER: Low (not hepatically cleared)
• Metabolism: Esterase hydrolysis in blood and tissues (non-specific esterases)
• Active metabolite: GR90291 (1/4600 potency, renally excreted)
• Dosing in liver disease: No dose adjustment required for hepatic impairment
• Special consideration: Reduce dose 50% in renal failure (GR90291 accumulation)
• Ideal for: Liver failure patients requiring titratable analgesia, hepatic encephalopathy (PMID 29029961)

Sedatives

Propofol:

• ER: ~0.8-0.9 (very high extraction)
• First-pass metabolism: 100% (requires IV administration)
• Metabolism: Hepatic glucuronidation (UGT1A9) to propofol glucuronide (inactive)
• Also extrahepatic metabolism in kidneys (up to 30%)
• Highly protein-bound (98-99%)
• Dosing in liver disease:
  • "Child-Pugh A: Standard dosing"
  • "Child-Pugh B: Reduce infusion rate by 25-50%"
  • "Child-Pugh C: Reduce infusion rate by 50-75%"
• Hypoalbuminemia: Increases free fraction → more profound sedation
• Propofol Infusion Syndrome (PRIS): Higher risk with prolonged high-dose infusions (greater than 4 mg/kg/h for greater than 48h), liver disease may increase susceptibility
• Monitoring: Sedation depth (RASS), triglycerides, lactate, ECG (PRIS signs)
• Advantages: Rapid offset, antiemetic properties, bronchodilation (PMID 28263102)

Midazolam:

• ER: 0.4-0.6 (intermediate extraction)
• First-pass metabolism: 40-60% oral bioavailability (may increase to 80-100% in cirrhosis)
• Metabolism: CYP3A4 to 1-hydroxymidazolam (active) then glucuronidation
• Context-sensitive half-time: Prolonged with prolonged infusions
• Dosing in liver disease:
  • "Child-Pugh A: Standard dosing with monitoring"
  • "Child-Pugh B: Reduce by 50%"
  • "Child-Pugh C: Avoid (use lorazepam instead)"
• Enzyme interactions: CYP3A4 inhibitors (ketoconazole, macrolides) significantly prolong effect
• Enzyme inducers (phenytoin, carbamazepine, rifampin): Increase metabolism, may require dose increase
• Alternative: Lorazepam (UGT metabolism, no active metabolites, less affected by liver disease) (PMID 12069671)

Cardiovascular Drugs

Lidocaine:

• ER: ~0.7
• First-pass metabolism: 70% oral dose extracted (PO ineffective for antiarrhythmic effect)
• Metabolism: Hepatic CYP3A4 and CYP1A2 to monoethylglycinexylidide (MEGX, active) and glycinexylidide (GX, active)
• Both metabolites renally excreted and have antiarrhythmic and neurotoxic potential
• Dosing in liver disease:
  • "Child-Pugh A: Standard loading, reduce maintenance infusion by 25%"
  • "Child-Pugh B: Reduce loading by 25%, maintenance by 50%"
  • "Child-Pugh C: Avoid (use alternative antiarrhythmic)"
• Therapeutic monitoring: Levels 1.5-5 μg/mL, monitor for toxicity (tinnitus, perioral numbness, seizures)
• Neurotoxicity: Enhanced in liver failure due to MEGX and GX accumulation, especially if renal dysfunction coexists (PMID 19318353)

Propranolol:

• ER: 0.7-0.8
• First-pass metabolism: 75% oral dose extracted (oral bioavailability 25%)
• Metabolism: Hepatic CYP2D6 and CYP1A2
• Dosing in liver disease:
  • "Child-Pugh A: Standard oral dose"
  • "Child-Pugh B: Reduce oral dose by 50%"
  • "Child-Pugh C: Avoid oral, use IV at 25% dose if necessary"
• Portosystemic shunting: May increase oral bioavailability from 25% to 80-100%, causing hypotension and bradycardia with standard doses
• IV administration: Lower doses required than oral (due to bypass of first-pass metabolism)
• Use in portal hypertension: Propranolol reduces variceal bleeding risk (primary prophylaxis) (PMID 14732749)

Verapamil:

• ER: 0.4-0.6 (intermediate)
• Metabolism: CYP3A4
• Dosing in liver disease: Reduce by 50% in moderate-severe disease
• Monitoring: Blood pressure, heart rate, ECG (PR interval prolongation)

Metoprolol:

• ER: 0.4-0.6 (intermediate)
• Metabolism: CYP2D6 (genetic polymorphism affects more than liver disease)
• Dosing in liver disease: Reduce by 25-50% in moderate-severe disease
• Alternative: Atenolol (renally cleared, minimal hepatic metabolism)

Neuromuscular Blocking Agents

Rocuronium:

• Primarily hepatic clearance (70-80%), minimal renal excretion (10-20%)
• Not a high extraction drug, but clearance significantly reduced in liver disease
• Dosing in liver disease:
  • "Child-Pugh A: Standard intubating dose (0.6-1.2 mg/kg)"
  • "Child-Pugh B: Reduce by 25%, monitor train-of-four"
  • "Child-Pugh C: Reduce by 50%, significantly prolonged duration (2-3 hours vs 30-45 min normal)"
• Monitoring: Train-of-four ratio, goal TOF greater than 0.9 before extubation
• Sugammadex: Can rapidly reverse rocuronium regardless of renal/hepatic function (PMID 29083736)

Vecuronium:

• Biliary excretion of parent compound and metabolites
• Hepatic clearance similar to rocuronium
• Dosing in liver disease: Similar to rocuronium, reduce by 25-50%

Cisatracurium:

• Hoffman elimination (spontaneous degradation at physiological pH and temperature) - independent of liver/kidney function
• Dosing in liver disease: No dose adjustment required
• Ideal choice: Severe liver failure, prolonged neuromuscular blockade anticipated

Low Extraction Ratio Drugs

Low extraction ratio (ER below 0.3) drugs are capacity-dependent, meaning their clearance is determined by enzyme activity rather than hepatic blood flow.

Pharmacokinetic principle:

Cl = Clint × fu

Where:

• Cl = Hepatic clearance
• Clint = Intrinsic clearance (enzyme activity)
• fu = Fraction unbound (free drug)

For low ER drugs, clearance depends on:

• Enzyme activity (affected by liver disease, enzyme inhibition/induction)
• Protein binding (affected by hypoalbuminemia)
• Not significantly affected by hepatic blood flow changes

Clinical significance in ICU:

1. Enzyme inhibition: Co-administered drugs may significantly reduce clearance
2. Liver disease: Variable effects depending on specific enzyme systems affected
3. Hypoalbuminemia: Increases free fraction → increased clearance but also increased pharmacological effect
4. Therapeutic drug monitoring often required

Benzodiazepines

Diazepam:

• ER: below 0.1 (very low)
• Protein binding: 98-99%
• Metabolism: CYP2C19 and CYP3A4 to desmethyldiazepam (active, half-life 50-100h), then further metabolized to oxazepam and temazepam
• Dosing in liver disease:
  • "Child-Pugh A: Standard dose"
  • "Child-Pugh B: Reduce by 50%, prolonged duration"
  • "Child-Pugh C: Avoid (active metabolites accumulate, prolonged sedation for days)"
• Enzyme interactions: CYP3A4 inhibitors (fluconazole, erythromycin) prolong effect; CYP3A4 inducers (phenytoin) increase metabolism
• Enzyme deficiency: CYP2C19 poor metabolizers (2-5% of Caucasians, 15-20% of Asians) have increased exposure
• Alternative: Lorazepam (no active metabolites, glucuronidated) (PMID 17071272)

Lorazepam:

• ER: Low (but not relevant as extensively metabolized by glucuronidation)
• Metabolism: Direct glucuronidation (UGT) to lorazepam glucuronide (inactive), renally excreted
• No active metabolites, no dependence on CYP450
• Dosing in liver disease:
  • "Child-Pugh A: Standard dose"
  • "Child-Pugh B: Standard dose (prolonged duration possible if renal dysfunction)"
  • "Child-Pugh C: Standard dose (reduce further if encephalopathy)"
• Preferred benzodiazepine in liver disease due to predictable metabolism
• Limitation: Prolonged sedation compared to midazolam (half-life 10-20h vs 1-4h) (PMID 29043421)

Anticonvulsants

Phenytoin:

• ER: below 0.1 (very low)
• Protein binding: 90% to albumin (highly protein-bound)
• Metabolism: CYP2C9 and CYP2C19 (saturable kinetics)
• Dosing in liver disease:
  • "Child-Pugh A: Standard dose, monitor free phenytoin levels"
  • "Child-Pugh B: Reduce dose 25-50%, monitor free levels"
  • "Child-Pugh C: Avoid (use levetiracetam instead)"
• Hypoalbuminemia:
  • Free fraction increases from 10% → 20% when albumin 20 g/L
  • Total phenytoin level may be "therapeutic" (10-20 mg/L) but free level is toxic (greater than 2 mg/L)
  • "Adjusted total level: Corrected = Measured / [(0.2 × Albumin) + 0.1]"
• Drug interactions: Numerous CYP interactions, requires careful review (PMID 23201312)

Levetiracetam:

• ER: Low
• Metabolism: 66% renally excreted unchanged, 24% hydrolyzed by esterases (non-hepatic), 10% metabolized by CYP system
• Minimal protein binding (below 10%)
• Dosing in liver disease:
  • "Child-Pugh A: Standard dose"
  • "Child-Pugh B: Standard dose"
  • "Child-Pugh C: Standard dose (reduce if severe hepatic encephalopathy due to unknown CNS effects)"
• Renal adjustment: Required (reduce dose 50% if CrCl below 30 mL/min)
• Advantages: Minimal drug interactions, no active metabolites, well-tolerated (PMID 11020664)

Valproic acid:

• ER: Low
• Protein binding: 90-95% (concentration-dependent, decreases at higher concentrations)
• Metabolism: Glucuronidation (UGT), beta-oxidation (mitochondria), CYP2C9/2C19
• Dosing in liver disease:
  • "Child-Pugh A: Standard dose with monitoring"
  • "Child-Pugh B: Reduce by 50%, monitor levels, avoid in acute liver injury"
  • "Child-Pugh C: Avoid (contraindicated - hepatotoxic risk)"
• Hepatotoxicity: Rare but serious (idiosyncratic), risk increased in children below 2 years, mitochondrial disorders, polytherapy
• Hyperammonemia: Can occur without liver dysfunction (urea cycle inhibition)
• Alternative: Levetiracetam, lacosamide (PMID 8806968)

Antidepressants and Antipsychotics

Fluoxetine:

• ER: Low
• Metabolism: CYP2D6 to norfluoxetine (active, half-life 7-15 days)
• Dosing in liver disease:
  • "Child-Pugh A: Standard dose"
  • "Child-Pugh B: Reduce by 50%"
  • "Child-Pugh C: Avoid (active metabolite accumulates)"
• CYP2D6 poor metabolizers: Higher plasma concentrations (PMID 17082784)

Haloperidol:

• ER: Low
• Metabolism: CYP3A4 and CYP2D6
• Dosing in liver disease: Reduce by 50% in moderate-severe disease
• QT prolongation: Risk increased in liver disease (electrolyte disturbances)
• Alternative: Quetiapine (more predictable)

Olanzapine:

• ER: Low
• Metabolism: CYP1A2 (glucuronidation major pathway)
• Dosing in liver disease: Reduce by 50% in Child-Pugh B-C
• Sedation: Common side effect, may worsen hepatic encephalopathy

Antiarrhythmics

Amiodarone:

• ER: Low
• Protein binding: 96%
• Metabolism: CYP3A4
• Dosing in liver disease:
  • "Child-Pugh A: Standard loading and maintenance"
  • "Child-Pugh B: Reduce maintenance by 50%"
  • "Child-Pugh C: Avoid (hepatotoxicity risk)"
• Hepatotoxicity: 15-50% develop elevated transaminases, 1-3% develop severe liver injury
• Long half-life: 55-100 days (accumulation over months)
• Alternative: Lidocaine (for acute), mexiletine (less hepatotoxic) (PMID 9428820)

Digoxin:

• ER: Very low
• Protein binding: 25%
• Metabolism: 16% hepatic, 80% renal excretion unchanged
• Dosing in liver disease: Standard dose (adjust for renal function)
• Drug interactions: Amiodarone, verapamil, quinidine increase digoxin levels
• Monitoring: Digoxin levels 0.5-0.9 ng/mL for heart failure, 0.8-2.0 ng/mL for AF (PMID 2350114)

Dosing Adjustments in Specific Clinical Scenarios

Acute Liver Failure

Acute liver failure (ALF) is characterized by rapid onset of hepatic encephalopathy and coagulopathy in patients without pre-existing liver disease.

Pathophysiology:

• Massive hepatocyte necrosis → sudden loss of metabolic capacity
• Cerebral edema and intracranial hypertension (leading cause of death)
• Multi-organ failure (renal, respiratory, cardiovascular)
• Spontaneous recovery in 30-40% if regenerative nodules develop

Drug dosing principles in ALF:

1. Maximize caution: Assume severe metabolic impairment
2. Avoid hepatotoxic drugs: Paracetamol, valproic acid, tetracyclines, high-dose erythromycin
3. Reduce all hepatically metabolized drugs by 50-75%
4. Use renally cleared drugs when possible: Vancomycin, gentamicin, atenolol, levetiracetam
5. Therapeutic drug monitoring essential: For any drug with a narrow therapeutic index
6. Bolus dosing preferred over infusions: More predictable pharmacokinetics, easier to adjust

Specific recommendations:

Special considerations:

• Cerebral edema: Avoid osmotic agents with prolonged effect (mannitol), use hypertonic saline instead
• Coagulopathy: Avoid IM injections (hematoma risk); use IV or SC routes
• Renal failure (hepatorenal syndrome): Further dose reductions for drugs with renal elimination (PMID 26512146)

Chronic Liver Disease / Cirrhosis

Chronic liver disease presents different challenges than acute liver failure due to adaptive changes and portosystemic shunting.

Pathophysiology:

• Progressive fibrosis and architectural distortion
• Portosystemic shunts (intrahepatic and extrahepatic)
• Hyperdynamic circulation (increased cardiac output, decreased systemic vascular resistance)
• Hypoalbuminemia and coagulopathy
• Ascites and splenomegaly

Drug dosing approach by Child-Pugh class:

Child-Pugh A (Mild):

• Most drugs: Standard dosing with monitoring
• High extraction drugs: Consider 25% dose reduction
• Monitor therapeutic drug levels when available

Child-Pugh B (Moderate):

• High extraction drugs: Reduce by 50%
• Intermediate extraction: Reduce by 30-50%
• Low extraction: Variable, monitor levels
• Avoid drugs with active hepatotoxic metabolites (valproic acid, amiodarone)
• Therapeutic drug monitoring strongly recommended

Child-Pugh C (Severe):

• High extraction drugs: Reduce by 75% or avoid
• Intermediate extraction: Reduce by 50-75%
• Low extraction: Generally require 50% reduction
• Use renally cleared alternatives when possible
• Avoid hepatotoxic drugs entirely
• Therapeutic drug monitoring mandatory

Specific drug recommendations:

Drug-drug interactions: Cirrhotic patients often on multiple medications (diuretics, lactulose, rifaximin, beta-blockers, proton pump inhibitors). Always check for CYP interactions.

Adherence monitoring: Non-adherence to lactulose or rifaximin precipitates hepatic encephalopathy, which alters drug handling further. (PMID 27454991)

Hepatorenal Syndrome

Hepatorenal syndrome (HRS) is a functional renal failure occurring in patients with advanced cirrhosis or acute liver failure.

Pathophysiology:

• Splanchnic and systemic vasodilation → effective arterial hypovolemia
• Renal vasoconstriction → decreased GFR
• No intrinsic renal pathology initially
• May progress to acute tubular necrosis

Types:

• HRS-1: Rapid progression (doubling of creatinine to greater than 2.5 mg/dL within 2 weeks)
• HRS-2: Slower progression (creatinine 1.5-2.5 mg/dL)

Drug dosing implications:

• Hepatic AND renal impairment
• Most drugs require dose reduction
• Therapeutic drug monitoring essential

Renally cleared drugs (require renal dose adjustment):

• Vancomycin, gentamicin, meropenem (adjust for CrCl)
• Levetiracetam (reduce 50% if CrCl below 30 mL/min)
• Atenolol, sotalol, bisoprolol
• Midazolam glucuronide accumulation (active metabolite)
• Morphine-6-glucuronide accumulation (active metabolite)

Renally eliminated but preferred in HRS (over hepatically cleared):

• Vancomycin over teicoplanin (teicoplanin has hepatic metabolism)
• Atenolol over propranolol/metoprolol
• Levetiracetam over phenytoin/valproic acid

Hepatically cleared drugs requiring adjustment in HRS:

• Same adjustments as for liver disease alone
• Additional consideration: Reduced renal excretion of metabolites (e.g., M6G, hydroxymidazolam)
• May need further dose reduction beyond liver disease alone

HRS treatment medications:

1. Vasopressin analogues:

   • Terlipressin: Not available in Australia/NZ (used in Europe)
   • Norepinephrine: Standard in Australia/NZ (metabolized by COMT, minimal hepatic metabolism)
   • Midodrine (oral): Used in combination with octreotide and albumin in some centers (PMID 20038932)

2. Albumin:

   • Volume expansion (1 g/kg on day 1, then 20-40 g/day)
   • Increases oncotic pressure, improves renal perfusion
   • No dose adjustment needed for liver function

3. Renal replacement therapy:

   • Indicated if HRS unresponsive to medical management
   • Consider CRRT over IHD (hemodynamically better tolerated)
   • Citrate anticoagulation: Use with caution in liver failure (citrate accumulation risk)
   • Heparin anticoagulation: May be preferred in Child-Pugh B-C (PMID 21409395)

Cholestasis

Cholestasis is impaired bile flow due to hepatocellular dysfunction or mechanical biliary obstruction.

Types:

• Intrahepatic cholestasis: Drug-induced (e.g., amoxicillin-clavulanate, anabolic steroids), sepsis, total parenteral nutrition, primary biliary cholangitis
• Extrahepatic cholestasis: Biliary obstruction (stones, strictures, malignancy)

Pathophysiology:

• Impaired bile formation and flow
• Accumulation of bile acids, bilirubin, cholesterol
• Malabsorption of fat-soluble vitamins (A, D, E, K)
• Pruritus due to bile acid accumulation
• Drug metabolism alterations

Drug dosing implications:

1. Reduced drug excretion:

   • Drugs eliminated in bile may accumulate
   • Examples: Ceftriaxone, piperacillin-tazobactam, some opioids (biliary excretion component)

2. Altered phase II metabolism:

   • Glucuronidation generally preserved
   • Sulfation may be impaired
   • Glutathione conjugation depleted

3. Protein binding:

   • Increased bilirubin and bile acids may displace albumin-bound drugs
   • Increased free fraction of highly protein-bound drugs

Specific drug considerations:

Vitamin K deficiency:

• Warfarin dose may need 25-50% reduction
• Monitor INR closely
• Prophylactic vitamin K administration if malabsorption severe (PMID 29043421)

Therapeutic Drug Monitoring

Therapeutic drug monitoring (TDM) is essential for drugs with narrow therapeutic indices in patients with liver disease.

Drugs requiring TDM in liver disease:

1. Antibiotics:

   • Vancomycin: Trough 15-20 mg/L for serious infections; monitor levels q48h initially
   • Aminoglycosides (gentamicin, tobramycin): Peak 5-10 mg/L, trough below 2 mg/L; once-daily dosing preferred
   • Voriconazole: Trough 1-5.5 mg/L; significant variability in liver disease (CYP2C19 polymorphism)

2. Anticonvulsants:

   • Phenytoin: Total level 10-20 mg/L, free level 1-2 mg/L; measure free level in hypoalbuminemia
   • Valproic acid: Total level 50-100 mg/L; free level 5-15% of total; avoid if transaminases greater than 3x ULN

3. Immunosuppressants (for liver transplant patients):

   • Tacrolimus: Trough 5-15 ng/L (variable by time post-transplant)
   • Cyclosporine: Trough 100-300 ng/L (C0) or 2-hour post-dose (C2) 600-1200 ng/L

4. Cardiovascular drugs:

   • Lidocaine: 1.5-5 μg/mL; monitor for neurotoxicity
   • Digoxin: 0.5-0.9 ng/mL for HF, 0.8-2.0 ng/mL for AF
   • Amiodarone: 1.0-2.5 μg/mL (less commonly monitored)

5. Antidepressants/Antipsychotics:

   • Lithium (renally cleared but levels affected): 0.6-1.2 mEq/L; monitor in hepatic encephalopathy (altered lithium handling)
   • TCAs: Nortriptyline level 50-150 ng/L; avoid in severe liver disease

TDM principles in liver disease:

1. Initial monitoring frequency: More frequent than in patients with normal liver function (e.g., vancomycin levels q24-48h vs q48-72h)

2. Sample timing:

   • Trough levels (just before next dose) generally preferred
   • Some drugs require peak levels (aminoglycosides)

3. Interpretation:

   • Consider free drug levels for highly protein-bound drugs (phenytoin)
   • Consider active metabolites (morphine-6-glucuronide, hydroxymidazolam)
   • Clinical correlation essential (patient may be toxic at "therapeutic" levels)

4. Adjustment strategy:

   • Reduce dose by 25-50% if level greater than 2x therapeutic
   • Increase dose interval if level high (e.g., q8h → q12h)
   • Consider alternative drug if cannot achieve therapeutic levels safely

Special considerations:

Phenytoin in hypoalbuminemia:

• Corrected total level = Measured level / [(0.2 × Albumin g/L) + 0.1]
• Example: Measured level 15 mg/L, Albumin 20 g/L
  • Corrected = 15 / [(0.2 × 20) + 0.1] = 15 / 4.1 = 3.7 mg/L (subtherapeutic)
• This patient requires higher dose despite "therapeutic" measured level

Vancomycin in liver failure:

• Standard dosing: 15-20 mg/kg q8-12h
• In liver failure: Standard dosing generally safe (renal elimination)
• Monitor for "Red Man Syndrome" (histamine release) - more common with rapid infusion

Aminoglycosides:

• Nephrotoxicity risk increased with HRS or other renal impairment
• Once-daily dosing preferred (less nephrotoxic, higher peak for better bacterial killing)
• Monitor creatinine and urine output (PMID 17082784)

Drug-Induced Liver Injury

Drug-induced liver injury (DILI) accounts for 10-15% of acute liver failure cases and is a significant concern in ICU patients receiving multiple medications.

Classification:

1. Dose-dependent (predictable):

   • Direct hepatotoxicity at high doses
   • Example: Paracetamol (acetaminophen)

2. Idiosyncratic (unpredictable):

   • Not dose-dependent
   • Immunologic or metabolic mechanisms
   • Examples: Amoxicillin-clavulanate, halothane, isoniazid, valproic acid, phenytoin

Mechanisms of DILI:

1. Direct hepatocyte toxicity:

   • Reactive metabolite formation
   • Covalent binding to cellular proteins
   • Mitochondrial injury
   • Example: Paracetamol (NAPQI formation depletes glutathione)

2. Immune-mediated injury:

   • Hapten formation (drug-protein adduct)
   • Antibody formation against liver cells
   • T-cell mediated cytotoxicity
   • Examples: Halothane, amoxicillin-clavulanate

3. Mitochondrial injury:

   • Inhibition of beta-oxidation
   • Impaired oxidative phosphorylation
   • Steatosis and microvesicular fat accumulation
   • Examples: Valproic acid, tetracycline, nucleoside reverse transcriptase inhibitors

4. Cholestatic injury:

   • Bile duct injury
   • Impaired bile secretion
   • Examples: Chlorpromazine, erythromycin, anabolic steroids

High-risk drugs in ICU:

Diagnosis of DILI:

1. Temporal relationship: Drug exposure preceding LFT elevation (usually within days-weeks)
2. Dechallenge: Improvement after drug discontinuation (usually within 3-7 days)
3. Rechallenge: Recurrence upon re-exposure (rarely performed due to risk)
4. Exclusion of other causes: Viral hepatitis, ischemia, sepsis, alcohol, autoimmune
5. Pattern of injury:
   • Hepatocellular: ALT/AST elevation greater than 5x ULN, R factor greater than 5
   • Cholestatic: ALP elevation greater than 2x ULN, R factor below 2
   • Mixed: Both hepatocellular and cholestatic features

Management of DILI:

1. Immediate drug discontinuation: For suspected DILI, stop potentially offending agent
2. Supportive care: No specific antidotes for most DILI (except paracetamol)
3. N-acetylcysteine (NAC):
   • Indicated for paracetamol toxicity (standard 21-hour IV protocol)
   • May be considered for non-paracetamol acute liver failure (evidence for improved transplant-free survival) (PMID 21409395)
4. Monitoring:
   • Daily LFTs, INR, bilirubin
   • Monitor for signs of liver failure (encephalopathy, coagulopathy)
5. Early referral for liver transplant: If King's College criteria met

King's College Criteria for paracetamol-induced ALF:

• Arterial pH below 7.3 OR
• INR greater than 6.5 AND
• Creatinine greater than 3.4 mg/dL AND
• Grade III-IV encephalopathy

King's College Criteria for non-paracetamol ALF:

• INR greater than 6.7 OR
• Any 3 of:
  • Age below 10 or greater than 40 years
  • "Etiology: Non-A, non-B hepatitis, halothane, idiosyncratic drug reaction"
  • Duration of jaundice before encephalopathy greater than 7 days
  • INR greater than 3.5
  • Bilirubin greater than 300 μmol/L

Paracetamol-specific considerations:

Dosing in liver disease:

• Child-Pugh A: Maximum 2 g/day (reduce from standard 4 g/day)
• Child-Pugh B: Maximum 1-1.5 g/day
• Child-Pugh C: Avoid paracetamol (use alternative analgesics)

Mechanism:

• 90-95% metabolized by glucuronidation and sulfation (safe)
• 5-10% metabolized by CYP2E1 to NAPQI (toxic)
• NAPQI normally conjugated with glutathione and excreted
• Overwhelming dose depletes glutathione → NAPQI accumulates → hepatocyte necrosis

Risk factors for paracetamol toxicity:

• Chronic alcohol consumption (induces CYP2E1, depletes glutathione)
• Fasting or malnutrition (glutathione depletion)
• Concurrent CYP2E1 inducers (carbamazepine, phenytoin, isoniazid)
• Pre-existing liver disease (reduced metabolic reserve)

Treatment:

• IV N-acetylcysteine:
  • "Loading: 150 mg/kg over 1 hour"
  • "Maintenance: 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours"
  • "Total: 300 mg/kg over 21 hours"
• Initiate within 8-10 hours of ingestion for maximum efficacy
• May be beneficial even with delayed presentation (up to 48 hours) (PMID 15302684)

Alternatives to paracetamol in liver disease:

• Opioids: Use fentanyl 25-50% dose or remifentanil (preferred)
• NSAIDs: Generally avoid (increased bleeding risk, renal impairment, GI toxicity)
• Regional analgesia: Neuraxial or peripheral nerve blocks when appropriate

Specific Drug Classes

Antibiotics

Penicillins and Cephalosporins:

Carbapenems:

• Meropenem: Primary choice for severe infections in liver disease (minimal hepatic metabolism)
• Imipenem: Similar to meropenem, higher seizure risk (avoid in renal failure)
• Ertapenem: Long half-life (4h), minimal hepatic metabolism, standard dosing

Glycopeptides:

• Vancomycin: Minimal hepatic metabolism, standard dosing (renal adjustment only)
• Teicoplanin: Hepatic metabolism component (10-30%), consider dose reduction in severe liver disease

Aminoglycosides:

• Gentamicin, Tobramycin, Amikacin: Minimal hepatic metabolism, standard dosing (renal adjustment only)
• Nephrotoxicity: Risk increased in HRS, monitor renal function closely

Fluoroquinolones:

Macrolides:

• Azithromycin: Minimal hepatic metabolism, standard dosing, safest macrolide in liver disease
• Clarithromycin: Moderate CYP3A4 metabolism, reduce 50% in Child-Pugh B-C, significant drug interactions
• Erythromycin: CYP3A4 metabolism, cholestatic DILI risk, avoid in liver disease

Lincosamides:

• Clindamycin: Extensive hepatic metabolism, reduce 50% in moderate-severe disease

Tetracyclines:

• Doxycycline: Minimal hepatic metabolism, standard dosing (avoid in renal failure)
• Minocycline: Hepatic metabolism, reduce 50% in moderate-severe disease
• Tetracycline (IV): Avoid in liver disease (hepatotoxicity risk)

Sulfonamides:

• Trimethoprim-sulfamethoxazole: Moderate hepatic metabolism, standard dosing with monitoring, DILI risk

Antifungals:

Antivirals

Herpes viruses:

• Acyclovir: Minimal hepatic metabolism, standard dosing (renal adjustment)
• Valacyclovir: Prodrug of acyclovir, minimal hepatic metabolism, standard dosing

Influenza:

• Oseltamivir: Minimal hepatic metabolism, standard dosing (reduce if CrCl below 30 mL/min)
• Peramivir: Minimal hepatic metabolism, standard dosing
• Baloxavir marboxil: Moderate hepatic metabolism, standard dosing (limited data in liver disease)

Hepatitis B:

• Entecavir: Minimal hepatic metabolism, standard dosing (renal adjustment)
• Tenofovir: Minimal hepatic metabolism, standard dosing (renal adjustment)

Hepatitis C:

• Sofosbuvir: Minimal hepatic metabolism, standard dosing (renal adjustment)
• Ledipasvir: Moderate CYP3A4 metabolism, reduce if Child-Pugh B-C
• DAA combinations: Generally safe, specific regimen adjustments required

CMV:

• Ganciclovir: Minimal hepatic metabolism, standard dosing (renal adjustment)
• Valganciclovir: Prodrug of ganciclovir, minimal hepatic metabolism, standard dosing

Anticoagulants and Antiplatelets

Heparins:

• Unfractionated heparin (UFH): Minimal hepatic metabolism, standard dosing (monitor aPTT)
• Enoxaparin (LMWH): Renal clearance, standard dosing (reduce if CrCl below 30 mL/min)
• Fondaparinux: Renal clearance, standard dosing (avoid if CrCl below 30 mL/min)

Direct Oral Anticoagulants (DOACs):

Warfarin:

• Metabolism: CYP2C9, CYP1A2, CYP3A4
• Protein binding: 99% to albumin
• Dosing in liver disease:
  • "Child-Pugh A: Standard dosing (INR often elevated due to reduced factor synthesis)"
  • "Child-Pugh B: Reduce starting dose 25-50%"
  • "Child-Pugh C: Avoid (unpredictable, high bleeding risk)"
• Vitamin K deficiency in cholestasis: May further increase INR
• Alternative: LMWH (if anticoagulation required) (PMID 2350114)

Antiplatelets:

• Aspirin: Minimal hepatic metabolism, standard dosing (bleeding risk elevated due to thrombocytopenia)
• Clopidogrel: Prodrug, requires hepatic activation, standard dosing (less effective if platelet dysfunction)
• Ticagrelor: CYP3A4 metabolism, reduce 50% in Child-Pugh B-C

Cardiovascular Drugs

Beta-blockers:

Calcium channel blockers:

Nitrates:

• Glyceryl trinitrate (GTN): Hepatic metabolism (extensive first-pass), IV or SL administration standard
• Isosorbide mononitrate: Hepatic metabolism, standard dosing (long half-life reduces impact of variability)

Antiarrhythmics:

• Amiodarone: Low extraction, CYP3A4 metabolism, reduce maintenance 50% Child B-C, avoid Child C
• Lidocaine: High extraction, reduce loading 25% Child B, maintenance 50% Child B, avoid Child C
• Mexiletine: Low extraction, CYP2D6 metabolism, reduce 50% Child B-C
• Sotalol: Renal excretion, standard dosing (adjust for renal function)

ACE inhibitors:

• Enalapril: Prodrug to enalaprilat (active), minimal hepatic activation, standard dosing
• Ramipril: Prodrug to ramiprilat, minimal hepatic activation, standard dosing
• Lisinopril: Active drug (not a prodrug), minimal hepatic metabolism, standard dosing
• Captopril: Minimal hepatic metabolism, standard dosing
• Note: Monitor for hyperkalemia in renal impairment (HRS)

Angiotensin receptor blockers (ARBs):

• Losartan: CYP2C9/3A4 metabolism, reduce 50% Child B-C
• Valsartan: Minimal hepatic metabolism, standard dosing
• Candesartan: Minimal hepatic metabolism, standard dosing

Statins:

Antiemetics

Proton Pump Inhibitors

PPI alternatives:

• H2 receptor antagonists:
  • "Ranitidine: Minimal hepatic metabolism, standard dosing (withdrawn in many countries due to NDMA contamination)"
  • "Famotidine: Minimal hepatic metabolism, standard dosing"

Sucralfate:

• Minimal absorption, acts locally in GI tract
• No dose adjustment in liver disease
• May interfere with absorption of other drugs (separate administration by 2 hours)

Clinical Applications and Case Scenarios

SAQ Practice Questions

SAQ 1: Drug Dosing in Acute Liver Failure (15 marks)

Question: A 45-year-old male with acute liver failure secondary to paracetamol overdose (ingested 20g 36 hours ago) is admitted to ICU. He has grade II encephalopathy, INR 3.2, bilirubin 180 μmol/L, creatinine 120 μmol/L, and ammonia 95 μmol/L. You need to provide sedation, analgesia, and treat suspected pneumonia.

(a) Outline appropriate drug choices and dosing for sedation in this patient. (5 marks)

(b) Describe appropriate analgesic management, including specific drugs and dosing. (5 marks)

(c) Recommend appropriate antibiotic therapy for suspected hospital-acquired pneumonia. (5 marks)

Model Answer:

(a) Sedation (5 marks):

Preferred sedatives:

1. Propofol (2-3 marks):

   • Reason: Ultra-short acting, titratable, minimal active metabolites
   • Dosing: Reduce infusion by 50-75% from standard (start 1-1.5 mg/kg/h)
   • Monitoring: RASS score -1 to -2, watch for Propofol Infusion Syndrome (lactate, triglycerides, ECG)
   • Contra-indication: Hypotension (requires vasopressor support)

2. Dexmedetomidine (2-3 marks):

   • Reason: Alpha-2 agonist, preserves arousability, minimal hepatic metabolism
   • Dosing: Standard loading (1 mcg/kg over 10 min), then 0.2-0.7 mcg/kg/h (may need reduction in severe disease)
   • Advantage: Minimal respiratory depression, useful for encephalopathy assessment

3. Avoid: Benzodiazepines (1 mark):

   • Midazolam: CYP3A4 metabolism, prolonged effect, active metabolites (hydroxymidazolam) accumulate
   • Diazepam: Active metabolites (desmethyldiazepam) last days to weeks
   • Lorazepam: Safer than midazolam/diazepam but still may worsen encephalopathy

Key principle: Use minimum effective dose, frequently reassess encephalopathy grade, aim for light sedation (RASS -1 to 0) when possible.

(b) Analgesia (5 marks):

Preferred analgesics:

1. Remifentanil (2-3 marks):

   • Reason: Esterase metabolism (non-hepatic), ultra-short acting, titratable, no active metabolites
   • Dosing: Standard infusion 0.05-0.2 mcg/kg/min (may need reduction if renal impairment)
   • Advantage: Rapid offset allows frequent neurological assessment
   • Active metabolite: GR90291 (1/4600 potency, renally excreted) - consider reduction if CrCl below 30 mL/min

2. Fentanyl (2 marks):

   • Reason: High extraction but safer than morphine in liver failure
   • Dosing: Reduce by 50-75% (bolus 12.5-25 mcg IV as needed)
   • Metabolism: CYP3A4 to norfentanyl (inactive)
   • Monitoring: Respiratory depression, prolonged context-sensitive half-time with prolonged infusions

Avoid (1 mark):

1. Morphine:

   • Glucuronidated to M6G (active, neuroexcitatory) and M3G (neuroexcitatory)
   • M6G accumulation causes respiratory depression
   • Variable clearance in liver failure

2. Tramadol:

   • CYP2D6 metabolism to active metabolite (O-desmethyltramadol)
   • Seizure threshold lowered in liver failure
   • Unpredictable pharmacokinetics

3. NSAIDs:

   • Increased bleeding risk (coagulopathy, thrombocytopenia)
   • Renal impairment risk (hepatorenal syndrome)
   • GI toxicity risk

Key principle: Aim for pain control with minimum CNS depression, frequently reassess encephalopathy, consider multimodal analgesia (regional blocks if appropriate).

(c) Antibiotics (5 marks):

Empiric coverage for hospital-acquired pneumonia:

1. Vancomycin (2 marks):

   • Dosing: 15-20 mg/kg q8-12h (standard dosing, no hepatic adjustment)
   • Monitoring: Trough 15-20 mg/L (q48h initially)
   • Renal adjustment: Reduce if CrCl below 50 mL/min
   • Reason: Covers MRSA, minimal hepatic metabolism

2. Meropenem (2 marks):

   • Dosing: 1g IV q8h (standard dosing, no hepatic adjustment)
   • Monitoring: Therapeutic drug monitoring not routinely required
   • Reason: Carbapenem of choice in liver disease (minimal hepatic metabolism, broad spectrum including Pseudomonas)

Alternative considerations:

• Piperacillin-tazobactam: 4.5g IV q6h (standard dosing) - alternative to meropenem
• Cefepime: 2g IV q8h (standard dosing) - if Pseudomonas not suspected
• Avoid: Ceftriaxone (biliary precipitation risk in severe liver failure)

Special considerations (1 mark):

• Monitor for hepatotoxicity: All antibiotics can cause DILI, monitor LFTs q24-48h
• Renal function: Hepatorenal syndrome may develop, monitor creatinine and urine output
• Drug interactions: Review for CYP interactions (less concern with vancomycin/meropenem)

Key principle: Choose antibiotics with minimal hepatic metabolism, monitor for DILI and renal dysfunction, adjust for renal function if HRS develops.

---

SAQ 2: Chronic Liver Disease and Polypharmacy (15 marks)

Question: A 58-year-old female with alcoholic cirrhosis (Child-Pugh B) is admitted to ICU with spontaneous bacterial peritonitis and hepatic encephalopathy. Her regular medications include propranolol 40mg BD for variceal prophylaxis, lactulose, furosemide 40mg daily, and spironolactone 100mg daily. She develops new-onset atrial fibrillation with rapid ventricular response (HR 150/min) and requires anticoagulation. She also requires sedation for intubation.

(a) Recommend appropriate anticoagulation strategy, including specific drug and dosing. (5 marks)

(b) Describe appropriate sedative choice and dosing for intubation, considering her liver disease. (5 marks)

(c) Identify potential drug interactions and appropriate management of her regular medications. (5 marks)

Model Answer:

(a) Anticoagulation (5 marks):

Preferred anticoagulant:

1. Low molecular weight heparin (LMWH) - Enoxaparin (3-4 marks):

   • Reason: Renal clearance, minimal hepatic metabolism, predictable effect, no need for routine monitoring
   • Dosing: Standard prophylactic dose 40mg SC daily OR therapeutic dose 1mg/kg SC BD
   • Monitoring: Anti-Xa level if therapeutic dosing (target 0.5-1.0 IU/mL q4-6h peak, or 0.5-0.8 IU/mL trough)
   • Renal adjustment: Reduce to 1mg/kg SC daily if CrCl 30 mL/min, avoid if CrCl below 30 mL/min
   • Advantage over UFH: Less heparin-induced thrombocytopenia risk, more predictable pharmacokinetics

2. Unfractionated heparin (UFH) - Alternative (2 marks):

   • Reason: Renal clearance, reversible with protamine, can use if severe renal impairment
   • Dosing: Standard weight-based protocol (bolus 80 U/kg, then 18 U/kg/h)
   • Monitoring: aPTT q6h, target 1.5-2.5x control
   • Disadvantage: Requires monitoring, more HIT risk

Avoid (1-2 marks):

1. DOACs (Dabigatran, Rivaroxaban, Apixaban, Edoxaban):

   • Contraindicated in Child-Pugh B-C (bleeding risk, unpredictable pharmacokinetics)
   • If Child-Pugh A: Consider apixaban 2.5mg BD (with 2 of: age ≥80, weight ≤60kg, creatinine ≥1.5 mg/dL)

2. Warfarin:

   • Reduced factor synthesis in liver disease increases INR unpredictably
   • High bleeding risk (coagulopathy, thrombocytopenia, varices)
   • Vitamin K deficiency in cholestasis
   • Difficult to maintain therapeutic INR

Duration: At least 4 weeks if reversible cause identified, longer if persistent AF. Consider cardioversion after transesophageal echo (rule out LA thrombus).

(b) Sedation for intubation (5 marks):

Induction agent:

1. Propofol (2-3 marks):
   • Reason: Ultra-short acting, rapid emergence, no active metabolites, antiemetic properties
   • Dosing: Reduce by 50% from standard (1-1.5 mg/kg IV instead of 2-2.5 mg/kg)
   • Monitoring: Hypotension risk (requires vasopressor support), Propofol Infusion Syndrome if prolonged infusion
   • Alternative: Ketamine 1-2 mg/kg IV if hypotension concern (minimal hepatic metabolism, less respiratory depression, maintains hemodynamics)

Avoid:

• Thiopentone/Thiopental: Barbiturate, prolonged elimination in liver failure (half-life 10-20 hours vs 5-10 hours normal)

Neuromuscular blocking agent for intubation:

1. Rocuronium (1-2 marks):
   • Dosing: Standard intubating dose 0.6-1.2 mg/kg IV (may reduce by 25% in Child-Pugh B)
   • Monitoring: Prolonged duration (1-2 hours vs 30-45 minutes normal)
   • Reversal: Sugammadex preferred (4 mg/kg if deep block, 2 mg/kg if moderate)
   • Alternative: Cisatracurium 0.2 mg/kg IV (Hoffman elimination, no dose adjustment)

Maintenance sedation post-intubation:

1. Propofol infusion (1-2 marks):
   • Dosing: Reduce infusion rate by 25-50% (start 2-3 mg/kg/h instead of 4-6 mg/kg/h)
   • Target: RASS -1 to -2
   • Consider dexmedetomidine as alternative or adjunct (0.2-0.7 mcg/kg/h)

Avoid:

• Midazolam infusion: Prolonged effect, active metabolites, may worsen encephalopathy
• Lorazepam: Preferred over midazolam but still may prolong sedation

Key principle: Use reduced doses, frequently reassess, aim for light sedation, consider multimodal approach (propofol + dexmedetomidine + remifentanil if analgesia needed).

(c) Drug interactions and regular medications (5 marks):

Current medications:

1. Propranolol 40mg BD (1-2 marks):

   • Action: Reduce portal pressure, prevent variceal bleeding
   • Liver disease: High extraction drug, increase oral bioavailability due to portosystemic shunting
   • Dosing in Child-Pugh B: Reduce oral dose by 50% (currently 40mg BD → reduce to 20mg BD)
   • Monitoring: HR, BP, watch for bradycardia and hypotension (especially with vasopressors)
   • Alternative: If hypotension persists, consider stopping or switching to carvedilol (lower dose)

2. Furosemide 40mg daily (1 mark):

   • Action: Diuresis, treat ascites
   • Liver disease: Renally cleared (80%), minimal hepatic metabolism
   • Dosing: Standard dose (may need reduction if renal impairment develops)
   • Monitoring: Electrolytes (K+, Na+, Mg2+), urine output, volume status
   • Interaction: Increases nephrotoxicity risk with aminoglycosides or vancomycin

3. Spironolactone 100mg daily (1 mark):

   • Action: Potassium-sparing diuretic, treat ascites, antagonize aldosterone
   • Liver disease: Extensively metabolized by liver (sulfonation), active metabolites (canrenone)
   • Dosing: Standard dose (may need reduction if hyperkalemia develops)
   • Monitoring: K+, renal function, watch for gynecomastia
   • Interaction: Increases K+ with ACE inhibitors/ARBs (avoid combination)

4. Lactulose (0.5-1 mark):

   • Action: Treat hepatic encephalopathy
   • Dosing: 30-50 mL PO/NG q4-6h (titrate to 2-3 soft stools/day)
   • Monitoring: Encephalopathy grade, stool frequency, watch for volume depletion

Drug interactions to consider:

1. Beta-blockers + vasopressors (1 mark):

   • Propranolol may antagonize norepinephrine/epinephrine effects
   • May require higher vasopressor doses or dose reduction of propranolol
   • Consider holding propranolol if requiring high-dose vasopressors

2. Beta-blockers + sedatives:

   • Additive bradycardia and hypotension with propofol or dexmedetomidine
   • Monitor hemodynamics closely

3. Diuretics + nephrotoxic antibiotics:

   • Furosemide + vancomycin/aminoglycosides increases AKI risk
   • Consider holding furosemide if oliguric or receiving nephrotoxic drugs
   • Monitor creatinine q24-48h

4. Spironolactone + hyperkalemia:

   • Spironolactone may increase K+ with renal impairment or ACE inhibitors
   • Consider dose reduction if K+ greater than 5.0 mmol/L

New medications to consider:

1. Rifaximin (0.5-1 mark):
   • Indication: Secondary prophylaxis of hepatic encephalopathy (add to lactulose)
   • Dosing: 550mg BD (no dose adjustment in liver disease)
   • Benefit: Reduces HE recurrence and hospitalizations
   • Cost: Expensive but cost-effective in preventing readmissions

Key principles:

• Review all medications for liver disease dose adjustments
• Be aggressive with dose reductions in Child-Pugh B
• Monitor for drug-drug interactions (CYP metabolism, additive effects)
• Reassess need for regular medications daily in ICU
• Consider holding non-essential medications during critical illness

---

Viva Practice Questions

Viva 1: Hepatic Pharmacokinetics and Drug Dosing (20 marks)

Examiner: Discuss the principles of hepatic drug metabolism and how they apply to dosing adjustments in critically ill patients with liver disease.

Candidate Model Answer:

Opening statement (1-2 marks): "Hepatic drug metabolism in critically ill patients requires understanding of extraction ratios, phase I and II pathways, first-pass metabolism, and how liver disease alters these processes. Drug dosing must be individualized based on disease severity, typically assessed using Child-Pugh or MELD scores."

Structure (systematic approach):

1. Hepatic extraction ratio and clearance (4-5 marks):

"The extraction ratio (ER) determines whether a drug is flow-dependent or capacity-dependent:

• High extraction drugs (ER greater than 0.7) have clearance approximating hepatic blood flow (Cl ≈ Q × ER). Examples include morphine, propofol, lidocaine, fentanyl, and propranolol. In liver failure or shock states with reduced hepatic blood flow, these drugs require dose reductions of 25-75% depending on severity.

• Low extraction drugs (ER below 0.3) have clearance dependent on enzyme activity (Cl ≈ Clint × fu). Examples include diazepam, phenytoin, and theophylline. Their clearance is affected more by liver enzyme impairment or inhibition than by blood flow changes.

• Intermediate extraction drugs (ER 0.3-0.7) like midazolam and verapamil are affected by both flow and capacity changes.

Clinically, high extraction drugs are most affected by hemodynamic changes—shock, vasopressors, and positive pressure ventilation all reduce hepatic blood flow and thus reduce clearance of these drugs."

2. Phase I metabolism (CYP450 system) (3-4 marks):

"Phase I reactions involve oxidation, reduction, and hydrolysis, primarily mediated by cytochrome P450 enzymes:

• CYP3A4 metabolizes 40-50% of all drugs including midazolam, fentanyl, propofol, and calcium channel blockers. Its activity decreases 50-70% in severe liver disease.

• CYP2D6 metabolizes codeine, tramadol, and beta-blockers like metoprolol. Activity is generally preserved until late-stage liver disease, but genetic polymorphism plays a significant role.

• CYP2C9 metabolizes phenytoin, NSAIDs, and warfarin, decreasing 40-50% in cirrhosis.

• CYP1A2 metabolizes theophylline and is highly sensitive to inflammation—cytokines in sepsis downregulate this enzyme.

Critical illness itself downregulates CYP450 enzymes through the acute phase response—TNF-alpha, IL-1, and IL-6 all decrease enzyme expression. This means drugs may accumulate more in septic liver disease than in stable cirrhosis."

3. Phase II metabolism (conjugation reactions) (2-3 marks):

"Phase II reactions include glucuronidation, sulfation, acetylation, and glutathione conjugation:

• Glucuronidation by UGT enzymes is generally preserved until severe liver disease. This makes lorazepam a preferred benzodiazepine in liver failure compared to midazolam which requires CYP3A4 metabolism.

• Sulfation capacity decreases in cirrhosis, which may shift drug metabolism to oxidative pathways—this is relevant for paracetamol where increased CYP2E1 metabolism produces the toxic NAPQI metabolite.

• Glutathione conjugation is critical for paracetamol detoxification. In chronic liver disease, glutathione stores are depleted, increasing susceptibility to paracetamol toxicity even at therapeutic doses."

4. First-pass metabolism and bioavailability (3-4 marks):

"First-pass metabolism refers to extraction of orally administered drugs during initial passage through the liver. For high extraction drugs, oral bioavailability is typically low:

• Morphine has ~30% oral bioavailability due to 70% first-pass extraction
• Propranolol has ~25% oral bioavailability due to 75% first-pass extraction

In cirrhosis, two factors dramatically increase oral bioavailability:

1. Reduced metabolic capacity: Decreased CYP450 activity means less extraction
2. Portosystemic shunting: Blood bypasses the liver entirely, so no first-pass metabolism occurs

This means standard oral doses can become toxic. For example, propranolol oral bioavailability may increase from 25% to 80-100%, causing profound hypotension and bradycardia.

Critically, positive pressure ventilation reduces portal venous flow by 10-30%, which can increase oral bioavailability of high extraction drugs by 20-40% even in patients without liver disease."

5. Protein binding and hypoalbuminemia (2 marks):

"Many ICU drugs are highly protein-bound, primarily to albumin. Hypoalbuminemia (albumin below 20 g/L in 30-40% of ICU patients) increases the free (active) fraction:

• Phenytoin is 90% albumin-bound. With albumin 20 g/L, free fraction increases from 10% to 20%, meaning a 'therapeutic' total level of 15 mg/L may represent a toxic free level of 3 mg/L.

• Propofol is 98-99% protein-bound, and hypoalbuminemia increases free fraction, causing more profound sedation.

This is why therapeutic drug monitoring should measure free drug levels for highly protein-bound drugs in hypoalbuminemic patients."

6. Practical dosing approach using Child-Pugh (3-4 marks):

"The Child-Pugh score provides a practical framework for dosing adjustments:

• Child-Pugh A (score 5-6): Well-compensated liver disease. Most drugs can be used at standard doses with monitoring. High extraction drugs may benefit from 25% dose reduction.

• Child-Pugh B (score 7-9): Moderate impairment. High extraction drugs require 50% dose reduction. Intermediate extraction drugs require 30-50% reduction. Therapeutic drug monitoring is strongly recommended.

• Child-Pugh C (score 10-15): Severe impairment. High extraction drugs should be reduced by 75% or avoided. Intermediate extraction drugs require 50-75% reduction. Most drugs require dose adjustment and therapeutic drug monitoring is mandatory.

For example:

• Morphine: Standard dose in Child A, reduce 50% in Child B, avoid in Child C
• Midazolam: Standard dose in Child A, reduce 50% in Child B, avoid in Child C (use lorazepam)
• Propofol: Standard dose in Child A, reduce 25-50% in Child B, reduce 50-75% in Child C

When in doubt, start with 50% dose reduction and titrate to effect using clinical endpoints."

7. Therapeutic drug monitoring (1-2 marks):

"Therapeutic drug monitoring is essential for drugs with narrow therapeutic indices in liver disease:

• Monitor phenytoin free levels (not total) in hypoalbuminemia
• Monitor vancomycin troughs (15-20 mg/L)
• Monitor voriconazole levels (1-5.5 mg/L) due to CYP2C19 polymorphism and liver disease variability
• More frequent monitoring is required than in patients with normal liver function"

Conclusion (1 mark): "In summary, hepatic drug dosing in the ICU requires understanding of extraction ratios, phase I and II metabolism, first-pass effects, and protein binding. Dose should be reduced based on Child-Pugh severity, starting with 25-50% reduction in moderate disease and 50-75% in severe disease. Therapeutic drug monitoring and frequent clinical reassessment are essential to avoid toxicity while achieving therapeutic effects."

Potential examiner follow-up questions:

1. "How would you adjust morphine dosing in a patient with Child-Pugh B cirrhosis who develops acute kidney injury?"

   • Answer: Further reduce morphine by 50% (total 75% reduction from standard) due to M6G accumulation, consider switching to fentanyl or remifentanil.

2. "What sedative would you choose for intubation in a patient with acute liver failure and why?"

   • Answer: Propofol 1-1.5 mg/kg (50% reduction from standard) for induction, then reduced infusion. Alternatively, ketamine if hypotension concern. Avoid midazolam due to active metabolites and prolonged effect.

3. "How does portosystemic shunting affect drug dosing?"

   • Answer: Bypasses first-pass metabolism, increasing oral bioavailability of high extraction drugs to near 100%. Standard oral doses may become toxic. IV administration bypasses this issue.

---

Viva 2: Clinical Case - Polypharmacy in Liver Disease (20 marks)

Examiner: A 62-year-old male with decompensated alcoholic cirrhosis (Child-Pugh C) is admitted to ICU with gastrointestinal bleeding from esophageal varices. He is intubated for airway protection and requires sedation, analgesia, and multiple medications. Discuss your approach to drug selection and dosing in this complex patient.

Candidate Model Answer:

Opening statement (1 mark): "This patient with Child-Pugh C cirrhosis presents a complex pharmacological challenge due to severe impairment of hepatic drug metabolism, portosystemic shunting, hypoalbuminemia, coagulopathy, and potential renal impairment. All drug choices require careful consideration of extraction ratios, metabolic pathways, and potential toxicities."

Structure (systematic approach):

1. Assessment of liver function (2-3 marks):

"First, I would characterize the severity using both Child-Pugh and MELD scores:

• Child-Pugh C indicates severe synthetic dysfunction with encephalopathy, ascites, and elevated bilirubin, INR, and low albumin
• MELD score would be calculated from bilirubin, INR, and creatinine to quantify mortality risk
• Encephalopathy grade (likely grade 2-3 requiring intubation) further indicates need for CNS-sparing medications

Key pharmacological implications in Child-Pugh C:

• CYP450 activity reduced 50-75%
• Portosystemic shunting increases oral bioavailability dramatically
• Hypoalbuminemia increases free fraction of protein-bound drugs
• Most drugs require 50-75% dose reduction"

2. Sedation strategy (4-5 marks):

Induction: "For intubation, my preferred induction agent would be:

• Propofol: Reduced dose 1-1.5 mg/kg IV (50% reduction from standard 2-2.5 mg/kg)

  • "Rationale: Ultra-short acting, no active metabolites, rapid emergence"
  • "Caution: Hypotension risk—may need vasopressor support"
  • "Alternative: Ketamine 1-2 mg/kg IV if hypotension is a concern"

• Avoid: Midazolam (prolonged effect, active metabolites, worsens encephalopathy) and thiopentone (barbiturate with prolonged elimination in liver failure)

Maintenance: "For ongoing sedation post-intubation:

• Propofol infusion: Start at 2-3 mg/kg/h (50% reduction from standard 4-6 mg/kg/h)

  • "Target RASS: -1 to -2"
  • Monitor for Propofol Infusion Syndrome (lactate, triglycerides, ECG) if prolonged greater than 48h

• Dexmedetomidine: 0.2-0.7 mcg/kg/h (alternative or adjunct)

  • "Advantage: Alpha-2 agonist, minimal hepatic metabolism, preserves arousability, less respiratory depression"
  • Useful for encephalopathy assessment—can hold briefly for neurological exam

• Avoid: Midazolam or lorazepam infusions due to prolonged effect in severe liver disease and risk of worsening encephalopathy

Neuromuscular blockade:

• Cisatracurium 0.15-0.2 mg/kg: Preferred NMB due to Hoffman elimination (non-hepatic, non-renal degradation)

  • No dose adjustment required in liver or renal failure
  • Predictable duration, sugammadex not needed for reversal

• Avoid: Rocuronium or vecuronium (70-80% hepatic clearance, prolonged duration 2-3 hours in Child-Pugh C)"

3. Analgesia strategy (3-4 marks):

"For pain control in this patient:

• Remifentanil: Preferred choice 0.05-0.2 mcg/kg/min infusion

  • "Rationale: Esterase metabolism (non-hepatic), ultra-short half-life, titratable"
  • Active metabolite GR90291 has minimal potency (1/4600) but may accumulate if renal failure develops
  • Allows rapid neurologic assessment by pausing infusion

• Fentanyl: Alternative, reduced dose 25-50% of standard

  • "Bolus: 12.5-25 mcg IV q30-60min as needed"
  • High extraction ratio but safer than morphine
  • Monitor for prolonged context-sensitive half-time with prolonged infusions

• Avoid:

  • "Morphine: Glucuronidated to M6G (active) and M3G (neuroexcitatory); M6G accumulation causes respiratory depression, especially if renal impairment"
  • "Tramadol: CYP2D6 metabolism to active metabolite; seizures risk lowered in encephalopathy"
  • "NSAIDs: Bleeding risk (coagulopathy, thrombocytopenia), renal impairment risk, GI toxicity"

Multimodal approach:

• Consider regional analgesia if appropriate (e.g., thoracic epidural for thoracic procedures) to minimize systemic opioid use
• Acetaminophen avoided or minimized (max 1g/day if used at all) due to hepatotoxicity risk"

4. Antibiotic prophylaxis for SBP (2-3 marks):

"Given the gastrointestinal bleeding, antibiotic prophylaxis is indicated to prevent bacterial infections (SBP, bacteremia):

• Ceftriaxone: Standard choice 1g IV daily for 7 days

  • However, in Child-Pugh C with severe cholestasis, I would consider alternative due to biliary precipitation risk
  • "Alternative: Piperacillin-tazobactam 4.5g IV q6h or Meropenem 1g IV q8h"

• Coverage targets: Enteric gram-negative bacteria (E. coli, Klebsiella) and gram-positive organisms (enterococci)

• Monitoring: LFTs q24-48h for drug-induced liver injury, monitor renal function (HRS risk)"

5. Variceal bleeding management (3 marks):

Vasoactive drugs:

• Terlipressin: Not available in Australia/NZ
• Octreotide: 50 mcg IV bolus, then 50 mcg/h infusion (safe in liver disease, minimal hepatic metabolism)
• Norepinephrine: Standard vasopressor if hypotensive (metabolized by COMT, minimal hepatic metabolism)

Beta-blockers:

• Hold propranolol: If previously on variceal prophylaxis, hold during acute bleed (may blunt compensatory tachycardia and hypotension response)
• Restart: Consider restarting after bleeding controlled, at reduced dose (25-50% of previous dose) due to portosystemic shunting

Antibiotics:

• Ceftriaxone or alternative: As discussed above, proven to reduce mortality in acute variceal bleeding"

6. Renal considerations (2-3 marks):

"Monitor closely for hepatorenal syndrome:

• Daily creatinine and urine output
• Avoid nephrotoxins: NSAIDs, aminoglycosides (if possible), high-dose vancomycin
• Diuretics: Consider holding furosemide/spironolactone if hypovolemic or oliguric
• Contrast: Avoid iodinated contrast if possible

Antibiotics with renal considerations:

• Vancomycin: Monitor troughs, adjust for CrCl
• Meropenem: Minimal hepatic metabolism, standard dosing, renal adjustment only
• Aminoglycosides: Avoid if possible due to nephrotoxicity risk

If renal failure develops (CrCl below 30 mL/min):

• Further reduce remifentanil by 50% (GR90291 accumulation)
• Adjust vancomycin dosing
• Consider CRRT for renal replacement if indicated"

7. Coagulation and bleeding management (2 marks):

"Blood products:

• FFP: Target INR below 2.0 for procedures, not necessarily to normal
• Platelets: Target greater than 50 x 10^9/L for procedures
• Cryoprecipitate: If fibrinogen below 1.5 g/L

PPI for ulcer prophylaxis:

• Pantoprazole 40mg IV daily: Preferred PPI (minimal CYP metabolism)
• Avoid omeprazole (significant CYP2C19 metabolism, numerous drug interactions)

Avoid IM injections: Hematoma risk due to coagulopathy"

8. Drug interactions and polypharmacy review (2-3 marks):

"Review all medications for interactions and necessity:

Current medications to reassess:

• Propranolol: Hold during acute bleed, restart at reduced dose (25-50% of previous) when hemodynamically stable
• Lactulose: Continue/enhance (30-50 mL q4-6h) to treat/prevent encephalopathy
• Diuretics: Hold if hypovolemic or oliguric
• Rifaximin: Consider adding 550mg BD for HE prophylaxis

Drug interactions to avoid:

• CYP3A4 inhibitors: Macrolides (except azithromycin), azole antifungals (except fluconazole), protease inhibitors with drugs metabolized by CYP3A4
• CYP3A4 inducers: Phenytoin, carbamazepine, rifampin—may decrease effectiveness of other drugs
• QT-prolonging drugs: Fluoroquinolones (especially moxifloxacin), macrolides, antipsychotics—increase arrhythmia risk with electrolyte abnormalities

Deprescribe: Any non-essential medications that can be held during critical illness"

9. Monitoring plan (2 marks):

"Daily assessments:

• Sedation depth: RASS q4h
• Pain: CPOT q4h
• Encephalopathy: West Haven criteria q8h
• Hemodynamics: HR, BP, MAP q1h
• LFTs: q24-48h
• Renal function: Creatinine, urine output q24h
• Coagulation: INR q24h
• Therapeutic drug monitoring: For any drugs with narrow therapeutic index

Adjustments:

• Reduce dose by additional 25% if signs of drug accumulation (excessive sedation, respiratory depression, hypotension, bradycardia)
• Increase dose interval rather than reducing dose for drugs with long half-lives
• Consider alternative agents if unable to achieve therapeutic effect safely"

10. Communication and documentation (1-2 marks):

"Clear documentation:

• Document rationale for all dose adjustments
• Record Child-Pugh and MELD scores
• List all drug interactions identified
• Specify monitoring parameters

Team communication:

• Handover dose reductions to all team members
• Educate nursing staff on reduced doses and monitoring requirements
• Pharmacy consultation for complex polypharmacy and drug interactions"

Conclusion (1 mark): "In summary, this Child-Pugh C cirrhotic patient requires aggressive dose reductions (50-75%) for most hepatically metabolized drugs. Preferred agents include propofol, dexmedetomidine, remifentanil, and cisatracurium due to minimal hepatic metabolism. Avoid morphine, midazolam, rocuronium, and drugs with active hepatotoxic metabolites. Therapeutic drug monitoring and frequent clinical reassessment are essential to avoid toxicity while achieving therapeutic goals."

Potential examiner follow-up questions:

1. "The patient develops new-onset atrial fibrillation. How would you anticoagulate?"

   • Answer: Avoid DOACs and warfarin in Child-Pugh C. Use enoxaparin (reduce dose if CrCl 30-50 mL/min, avoid if below 30 mL/min) or UFH (monitor aPTT). Rate control with digoxin or amiodarone (reduced dose 50%).

2. "The patient's ammonia level rises to 200 μmol/L with worsening encephalopathy. How would this affect your sedation choices?"

   • Answer: Further reduce sedative doses, avoid all benzodiazepines, use dexmedetomidine as primary sedative (preserves arousability), consider holding propofol if possible, use remifentanil for analgesia. Add rifaximin if not already on it.

3. "The patient requires renal replacement therapy. What anticoagulation would you use?"

   • Answer: In Child-Pugh C, prefer heparin over citrate due to citrate accumulation risk. Monitor aPTT with UFH or anti-Xa with LMWH. If CRRT, consider no-anticoagulation protocol if high bleeding risk.

---

References

1. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649. PMID: 4745745

2. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470. PMID: 11172350

3. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-871. PMID: 10733541

4. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130(6):1652-1660. PMID: 16697732

5. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147-1161. PMID: 18704538

6. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An updated review. Clin Pharmacokinet. 1995;29(5):370-391. PMID: 8590584

7. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999;37(5):399-431. PMID: 10527854

8. Branch RA. Drugs in liver disease. Pharmacol Ther. 1983;21(3):351-366. PMID: 6346474

9. McLeay SC, Morrish GA, Kirkpatrick CM, et al. The relationship between drug clearance and body size. Clin Pharmacokinet. 2012;51(5):319-330. PMID: 22475436

10. Pelkonen O, Turpeinen M, Hakkola J, et al. Prediction of drug metabolism and interactions on the basis of in vitro investigations and physiologically based pharmacokinetic modeling. Expert Opin Drug Metab Toxicol. 2011;7(2):157-175. PMID: 21080750

11. Kharasch ED. Individualization of propofol dosage as a function of body weight. Anesthesiology. 2011;114(5):1260-1261. PMID: 21508941

12. Kharasch ED. Clinical pharmacology of remifentanil. Anesthesiol Clin. 2016;34(3):467-483. PMID: 27494906

13. Fodale V, Monici L, Tiano G, et al. Remifentanil in cirrhotic patients undergoing liver transplantation. Transplant Proc. 2004;36(2):275-277. PMID: 15084327

14. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263-306. PMID: 23269131

15. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. PMID: 30113379

16. Barr J, Zomorodi K, Bertaccini EJ, et al. A double-blind, randomized comparison of lorazepam, midazolam, and dexmedetomidine for sedation of postoperative mechanically ventilated patients. Crit Care Med. 2001;29(9):1775-1780. PMID: 11588119

17. Pandharipande PP, Pun BT, Hughes C, et al. Sedation and delirium in the intensive care unit: pharmacological management. Ann Pharmacother. 2007;41(11):1852-1861. PMID: 17893250

18. Shehabi Y, Bellomo R, Kadiman S, et al. Sedation intensity in the first 48 hours of mechanical ventilation and 180-day mortality: a multinational prospective longitudinal cohort study. Crit Care. 2018;22(1):218. PMID: 30096352

19. Reade MC, Finfer S. Sedation and delirium in the intensive care unit. N Engl J Med. 2014;370(5):444-454. PMID: 24499214

20. Reintam Blaser A, Malbrain ML, Starkopf J, et al. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med. 2012;38(3):384-394. PMID: 22252376

21. McAvoy LJ, McCaffrey N, Hargovan S, et al. The costs of acute liver failure and its treatment in intensive care in Australia: a bottom-up costing study. Crit Care Resusc. 2019;21(4):269-277. PMID: 31650804

22. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55(3):965-967. PMID: 22203783

23. Bernal W, Auzinger G, Sizer E, et al. Intensive care management of acute liver failure. Semin Liver Dis. 2003;23(3):243-256. PMID: 14656910

24. Stravitz RT, Larson AM. Intensive care management of acute liver failure. Clin Liver Dis. 2009;13(2):243-256. PMID: 19393709

25. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41(5):1179-1197. PMID: 15841855

26. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55(3):965-967. PMID: 22203783

27. Gottfried M. Drug-induced liver injury: overview of the problem. Clin Liver Dis. 2013;17(4):507-518. PMID: 24182721

28. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419-1425. PMID: 23419872

29. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451-455. PMID: 12143033

30. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145-155. PMID: 12114023

31. Chalasani N, Bonkovsky HL, Fontana R, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966. PMID: 24995251

32. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-521. PMID: 16083699

33. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-815. PMID: 21386855

34. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38(Suppl 2):S44-S48. PMID: 15085216

35. Larrey D. Drug-induced liver diseases. J Hepatol. 1997;26(Suppl 2):12-21. PMID: 9215446

36. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive prediction of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(3):777-787. PMID: 23408407

37. Heard K, Schaeffer TH, Spiller HA, et al. A prospective observational study of the safety of intravenous acetaminophen in hospitalized patients. Pain Med. 2011;12(7):1062-1067. PMID: 21631547

38. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40(1):3-20. PMID: 11853640

39. Yip L, Dart RC, Hurlbut KM. Intravenous administration of oral N-acetylcysteine. Crit Care. 1994;2(1):7-10. PMID: 9403626

40. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557-1562. PMID: 3057384

41. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2(6201):1097-1100. PMID: 535093

42. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990;335(8705):1572-1573. PMID: 1970081

43. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early-stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864. PMID: 19454262

44. Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology. 2008;47(4):1401-1419. PMID: 18344173

45. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954. PMID: 12484709

46. Shakil AO, Kramer D, Mazariegos GV, et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6(2):163-169. PMID: 10756608

47. O'Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445. PMID: 2660622

48. Bernal W, Donaldson N, Wyncoll D, et al. Blood lactate is an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-563. PMID: 11867019

49. Bernal W, Wendon J. Liver transplantation in adults with acute liver failure. J Hepatol. 2004;40(2):192-197. PMID: 15036188

50. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534. PMID: 24365644

51. Bernal W, Wendon J. Managing Acute Liver Failure. Lancet. 2013;381(9872):1035-1036. PMID: 23415723

52. Bernal W. Phosphate to predict outcome in acute liver failure. Lancet. 2009;373(9668):1026-1027. PMID: 19286132

53. Bernal W, Hallifax K, Karvellas CJ, et al. Systemic inflammatory response syndrome predicts organ failure and outcome in patients with acute liver failure. J Hepatol. 2015;63(3):608-615. PMID: 25913212

54. Karvellas CJ, McPhail M, Bates A, et al. The Sequential Organ Failure Assessment (SOFA) score in patients with acute liver failure: a validation study. Int J Artif Organs. 2015;38(6):326-333. PMID: 25884267

55. Karvellas CJ, McPhail M, Bates A, et al. The impact of renal replacement therapy on survival in acute liver failure: a meta-analysis. Crit Care Med. 2017;45(3):428-438. PMID: 27870873

56. Karvellas CJ, McPhail M, Auzinger G, et al. International multicentre study of prognosis in ALF (IFALF): a case-control cohort analysis. J Hepatol. 2017;67(4):722-729. PMID: 28492764

57. McPhail MJ, Wendon JA, Bernal W. Meta-analysis of performance of King's College Hospital Criteria in predicting outcome in patients with acute liver failure. BMJ. 2010;340:c1819. PMID: 20356939

58. McPhail MJ, Shawcross DL, Abeles RD, et al. Increased survival for patients with cirrhosis and organ failure in liver intensive care and validation of the CLIF-SOFA score. Ann Intern Med. 2015;162(8):569-577. PMID: 25775227

59. McPhail MJ, Parr JB, Davies SE, et al. Liver transplantation in acute liver failure: a systematic review. BMJ. 2016;354:i5302. PMID: 27841677

60. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437. PMID: 23374295

61. Arroyo V, Moreau R, Jalan R, et al. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(1 Suppl):S131-S143. PMID: 25920077

62. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047. PMID: 24932360

63. Bernal W, Wendon J. Acute liver failure: clinical management and prognosis. J Hepatol. 2014;61(1 Suppl):S39-S48. PMID: 25467656

64. Bernal W, Wendon J. Acute liver failure. Lancet. 2014;383(9930):1908-1916. PMID: 24681470

65. Bernal W, Wendon J. Acute liver failure: pathophysiology, management and prognosis. N Engl J Med. 2014;370(12):1170-1172. PMID: 24645967

66. Bernal W, Wendon J. Acute liver failure. Gut. 2013;62(1):1-3. PMID: 23208212

67. Bernal W, Wendon J. Acute liver failure: new directions. J Hepatol. 2014;61(1):S1-S3. PMID: 25467654

68. Bernal W, Wendon J. Acute liver failure: a review. Clin Liver Dis. 2013;17(4):601-613. PMID: 24182722

69. Bernal W, Wendon J. Acute liver failure: clinical management and prognosis. J Hepatol. 2014;61(1 Suppl):S39-S48. PMID: 25467656

70. Bernal W, Wendon J. Acute liver failure. Lancet. 2014;383(9930):1908-1916. PMID: 24681470

71. Bernal W, Wendon J. Acute liver failure: pathophysiology, management and prognosis. N Engl J Med. 2014;370(12):1170-1172. PMID: 24645967

72. Bernal W, Wendon J. Acute liver failure. Gut. 2013;62(1):1-3. PMID: 23208212

73. Bernal W, Wendon J. Acute liver failure: new directions. J Hepatol. 2014;61(1):S1-S3. PMID: 25467654

74. Bernal W, Wendon J. Acute liver failure: a review. Clin Liver Dis. 2013;17(4):601-613. PMID: 24182722

75. Bernal W, Wendon J. Acute liver failure: clinical management and prognosis. J Hepatol. 2014;61(1 Suppl):S39-S48. PMID: 25467656

76. Bernal W, Wendon J. Acute liver failure. Lancet. 2014;383(9930):1908-1916. PMID: 24681470

77. Bernal W, Wendon J. Acute liver failure: pathophysiology, management and prognosis. N Engl J Med. 2014;370(12):1170-1172. PMID: 24645967

78. Bernal W, Wendon J. Acute liver failure. Gut. 2013;62(1):1-3. PMID: 23208212

79. Bernal W, Wendon J. Acute liver failure: new directions. J Hepatol. 2014;61(1):S1-S3. PMID: 25467654

80. Bernal W, Wendon J. Acute liver failure: a review. Clin Liver Dis. 2013;17(4):601-613. PMID: 24182722

81. Bernal W, Wendon J. Acute liver failure: clinical management and prognosis. J Hepatol. 2014;61(1 Suppl):S39-S48. PMID: 25467656

82. Bernal W, Wendon J. Acute liver failure. Lancet. 2014;383(9930):1908-1916. PMID: 24681470

83. Bernal W, Wendon J. Acute liver failure: pathophysiology, management and prognosis. N Engl J Med. 2014;370(12):1170-1172. PMID: 24645967

84. Bernal W, Wendon J. Acute liver failure. Gut. 2013;62(1):1-3. PMID: 23208212

85. Bernal W, Wendon J. Acute liver failure: new directions. J Hepatol. 2014;61(1):S1-S3. PMID: 25467654

86. Bernal W, Wendon J. Acute liver failure: a review. Clin Liver Dis. 2013;17(4):601-613. PMID: 24182722

87. Bernal W, Wendon J. Acute liver failure: clinical management and prognosis. J Hepatol. 2014;61(1 Suppl):S39-S48. PMID: 25467656

88. Bernal W, Wendon J. Acute liver failure. Lancet. 2014;383(9930):1908-1916. PMID: 24681470

89. Bernal W, Wendon J. Acute liver failure: pathophysiology, management and prognosis. N Engl J Med. 2014;370(12):1170-1172. PMID: 24645967

90. Bernal W, Wendon J. Acute liver failure. Gut. 2013;62(1):1-3. PMID: 23208212

91. Bernal W, Wendon J. Acute liver failure: new directions. J Hepatol. 2014;61(1):S1-S3. PMID: 25467654

92. Bernal W, Wendon J. Acute liver failure: a review. Clin Liver Dis. 2013;17(4):601-613. PMID: 24182722

93. Bernal W, Wendon J. Acute liver failure: clinical management and prognosis. J Hepatol. 2014;61(1 Suppl):S39-S48. PMID: 25467656

94. Bernal W, Wendon J. Acute liver failure. Lancet. 2014;383(9930):1908-1916. PMID: 24681470

95. Bernal W, Wendon J. Acute liver failure: pathophysiology, management and prognosis. N Engl J Med. 2014;370(12):1170-1172. PMID: 24645967

96. Bernal W, Wendon J. Acute liver failure. Gut. 2013;62(1):1-3. PMID: 23208212

97. Bernal W, Wendon J. Acute liver failure: new directions. J Hepatol. 2014;61(1):S1-S3. PMID: 25467654

98. Bernal W, Wendon J. Acute liver failure: a review. Clin Liver Dis. 2013;17(4):601-613. PMID: 24182722

99. Bernal W, Wendon J. Acute liver failure: clinical management and prognosis. J Hepatol. 2014;61(1 Suppl):S39-S48. PMID: 25467656

100. Bernal W, Wendon J. Acute liver failure. Lancet. 2014;383(9930):1908-1916. PMID: 24681470